Smad3 antibody | knockout validation | Zymed (Thermo Fisher) 51-1500
DOI
//dx.doi.org/10.13070/ko.en.6.1865
Date
2016-11-25

This is a knockout-validated antibody summary, based on the publication "Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Antibody information

Rabbit polyclonal

Company: Zymed (Thermo Fisher Scientific)

Antibody: Smad3

Catalog number: 51-1500

Summary: Rabbit polyclonal antibody raised against a synthetic 20 amino acid peptide corresponding to central region of the human Smad3 linker domain. Supplier recommended for flow cytometry, ICC, IHC, WB and elisa. Antigen affinity-purified. Reacts with human Smad3.

Validation Method

Western blot

Sample

Lysates of wild-type and Smad3 -/- mouse embryonic fibroblasts.

Primary incubation

Anti-Smad3 antibody.

Figure

See Figure 3 in [1].

Disclaimer

If the antibody described in this summary is a polyclonal antibody, since polyclonal antibodies are of limited quantity, please inquire the supplier whether any current polyclonal antibody with the same catalog number is exactly the same as the one described in this summary. Sometimes, different bleeds or different animals are used, usually with a different lot number. In such cases, the result in this summary may not apply to the new antibody with the same catalog number.

References
  1. Daniels C, Wilkes M, Edens M, Kottom T, Murphy S, Limper A, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004;114:1308-16 pubmed